Accéder au contenu
Merck

Transcription factor-mediated reprogramming of fibroblasts to expandable, myelinogenic oligodendrocyte progenitor cells.

Nature biotechnology (2013-04-16)
Fadi J Najm, Angela M Lager, Anita Zaremba, Krysta Wyatt, Andrew V Caprariello, Daniel C Factor, Robert T Karl, Tadao Maeda, Robert H Miller, Paul J Tesar
RÉSUMÉ

Cell-based therapies for myelin disorders, such as multiple sclerosis and leukodystrophies, require technologies to generate functional oligodendrocyte progenitor cells. Here we describe direct conversion of mouse embryonic and lung fibroblasts to induced oligodendrocyte progenitor cells (iOPCs) using sets of either eight or three defined transcription factors. iOPCs exhibit a bipolar morphology and global gene expression profile consistent with bona fide OPCs. They can be expanded in vitro for at least five passages while retaining the ability to differentiate into multiprocessed oligodendrocytes. When transplanted to hypomyelinated mice, iOPCs are capable of ensheathing host axons and generating compact myelin. Lineage conversion of somatic cells to expandable iOPCs provides a strategy to study the molecular control of oligodendrocyte lineage identity and may facilitate neurological disease modeling and autologous remyelinating therapies.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps anti-Olig-2, Chemicon®, from rabbit
Sigma-Aldrich
Anticorps anti-protéine associée aux microtubules 2 (MAP2), Chemicon®, from rabbit
Sigma-Aldrich
Anticorps anti-MOG (glycoprotéine de myéline des oligodendrocytes), clone 8-18C5, Chemicon®, from mouse
Sigma-Aldrich
Anticorps anti-glycoprotéine associée à la myéline, clone 513, clone 513, Chemicon®, from mouse